The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Preformed albumin corona, a protective coating for nanoparticles based drug delivery system
Abstract
The non-specific interaction between nanoparticles (NPs) and plasma proteins occurs immediately after NPs enter the blood, resulting in the formation of the protein corona that thereafter replaces the original NPs and becomes what the organs and cells really see. Consequently, the in vivo fate of NPs and the biological responses to the NPs are changed. This is one substantial reason for the two main problems of the NPs based drug delivery system, i.e. nanotoxicity and rapid clearance of NPs from the blood after intravenous injection. Here, we demonstrate the successful application of the preformed albumin corona in inhibiting the plasma proteins adsorption and decreasing the complement activation, and ultimately in prolonging the blood circulation time and reducing the toxicity of the polymeric PHBHHx NPs. Since the interaction of proteins with various nano-materials and/or -particles is ubiquitous, pre-forming albumin corona has a great potential to be a versatile strategy for optimizing the NPs based drug delivery system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, carriers for delivering triptolide still face challenges, including uncontrolled drug release before reaching the target site, rapid clearance by the mononuclear phagocytic system (MPS) [265], and uncertain biological safety [266].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [265]
Citations
Cites
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., & Dawson, K. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107583h · Cited by 1,835
Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758
Time Evolution of the Nanoparticle Protein Corona
Casals, E., Pfaller, T., Duschl, A., Oostingh, G. J., & Puntes, V. (2010) · ACS Nano · doi:10.1021/nn901372t · Cited by 1,211
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Flagged first, then by citations
Research works printed but not linked: 26
- Tenne, 2006, Inorganic nanotubes and fullerene-like nanoparticles, Nat Nanotechnol, 1, 103, 10.1038/nnano.2006.62 · DOI
- Lalatsa, 2012, Amphiphilic poly(L-amino acids) – new materials for drug delivery, J Control Release, 161, 523, 10.1016/j.jconrel.2012.04.046 · DOI
- Peng, 2012, A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles, Biomaterials, 33, 1583, 10.1016/j.biomaterials.2011.10.072 · DOI
- Lalatsa, 2012, A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain, Mol Pharm, 9, 1665, 10.1021/mp300009u · DOI
- Peng, 2013, Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin, Acta Biomater, 9, 5063, 10.1016/j.actbio.2012.09.034 · DOI
- Chertok, 2011, Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers, Biomaterials, 32, 6245, 10.1016/j.biomaterials.2011.05.004 · DOI
- Zhao, 2012, Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend, Biomaterials, 33, 1948, 10.1016/j.biomaterials.2011.11.051 · DOI
- Bawa, 2011, Regulating nanomedicine – can the FDA handle it?, Curr Drug Deliv, 8, 227, 10.2174/156720111795256156 · DOI
- Peng, 2010, Mechanisms of phospholipid complex loaded nanoparticles enhancing the oral bioavailability, Mol Pharm, 7, 565, 10.1021/mp900274u · DOI
- Cedervall, 2007, Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles, Proc Natl Acad Sci U S A, 104, 2050, 10.1073/pnas.0608582104 · DOI · Paper page
- Lindman, 2007, Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity, Nano Lett, 7, 914, 10.1021/nl062743+ · DOI
- Cedervall, 2007, Detailed identification of plasma proteins adsorbed on copolymer nanoparticles, Angew Chem Int Ed Engl, 46, 5754, 10.1002/anie.200700465 · DOI
- Lynch, 2008, Protein-nanoparticle interactions, Nano Today, 3, 40, 10.1016/S1748-0132(08)70014-8 · DOI
- Mahmoudi, 2011, Protein-nanoparticle interactions: opportunities and challenges, Chem Rev, 111, 5610, 10.1021/cr100440g · DOI
- Monopoli, 2012, Biomolecular coronas provide the biological identity of nanosized materials, Nat Nanotechnol, 7, 779, 10.1038/nnano.2012.207 · DOI · Paper page
- Lundqvist, 2011, The evolution of the protein corona around nanoparticles: a test study, ACS Nano, 5, 7503, 10.1021/nn202458g · DOI
- Lundqvist, 2008, Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts, Proc Natl Acad Sci U S A, 105, 14265, 10.1073/pnas.0805135105 · DOI
- Ruh, 2012, Identification of serum proteins bound to industrial nanomaterials, Toxicol Lett, 208, 41, 10.1016/j.toxlet.2011.09.009 · DOI
- Clift, 2010, The effects of serum on the toxicity of manufactured nanoparticles, Toxicol Lett, 198, 358, 10.1016/j.toxlet.2010.08.002 · DOI
- Maiorano, 2010, Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response, ACS Nano, 4, 7481, 10.1021/nn101557e · DOI
- Shang, 2007, Unfolding of ribonuclease A on silica nanoparticle surfaces, Nano Lett, 7, 1991, 10.1021/nl070777r · DOI
- Shemetov, 2012, Molecular interaction of proteins and peptides with nanoparticles, ACS Nano, 6, 4585, 10.1021/nn300415x · DOI
- Ehrenberg, 2009, The influence of protein adsorption on nanoparticle association with cultured endothelial cells, Biomaterials, 30, 603, 10.1016/j.biomaterials.2008.09.050 · DOI · Paper page
- Ge, 2011, Binding of blood proteins to carbon nanotubes reduces cytotoxicity, Proc Natl Acad Sci U S A, 108, 16968, 10.1073/pnas.1105270108 · DOI
- Wang, 2011, Soft interactions at nanoparticles alter protein function and conformation in a size dependent manner, Nano Lett, 11, 4985, 10.1021/nl202940k · DOI
- Lesniak, 2012, Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells, ACS Nano, 6, 5845, 10.1021/nn300223w · DOI
Cited by
Sorted by citations
Exosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009
Ha, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
Kim, M. S., Haney, M. J., Zhao, Y., Yuan, D., Deygen, I., Klyachko, N. L., Kabanov, A. V., & Batrakova, E. V. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.09.011 · Cited by 663
Xu, X., Liang, Y., Li, X., Ouyang, K., Wang, M., Cao, T., Li, W., Liu, J., Xiong, J., Li, B., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120539 · Cited by 377
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Metadata
- Authors
- Peng, Q., Zhang, S., Yang, Q., Zhang, T., Wei, X.-Q., Jiang, L., Zhang, C.-L., Chen, Q.-M., Zhang, Z.-R., & Lin, Y.-F.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 34
- Issue
- 33
- Pages
- 8521-8530
- ISSN
- 0142-9612
- Cited by
- 366
- References
- 6
- Language
- en
- Funders
- National Natural Science Foundation of China (81071273, 31170929)
- Young Faculty Science Foundation of Sichuan University (2012SCU11100)
- Foundation of State Key Laboratory of Oral Diseases (SKLODYISF2012-08)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review